Romosozumab increases bone mineral density post-menopause

Romosozumab increases bone mineral density post-menopause
Romosozumab seems safe and effective for increasing bone mineral density in postmenopausal women with low bone mineral density, according to a study published online Jan. 1 in the New England Journal of Medicine.

(HealthDay)—Romosozumab seems safe and effective for increasing bone mineral density in postmenopausal women with low bone mineral density, according to a study published online Jan. 1 in the New England Journal of Medicine.

Michael R. McClung, M.D., from the Oregon Osteoporosis Center in Portland, and colleagues conducted a phase 2 study to examine the efficacy and safety of romosozumab over a 12-month period in 419 , aged 55 to 85 years of age, with low density. Participants were randomized to receive subcutaneous romosozumab every month (70, 140, or 210 mg) or every three months (140 or 210 mg), placebo, or an active comparator (70 mg weekly alendronate or 20 µg daily teriparatide).

The authors identified significant increases in bone mineral density at the lumbar spine with all dose levels of romosozumab, including a 11.3 percent increase with the 210-mg monthly dose, compared with a 0.1 percent decrease with placebo and 4.1 and 7.1 percent increases with alendronate and teriparatide, respectively. Large increases in bone mineral density were seen at the total hip and femoral neck, as well as transitory increases in markers with romosozumab, while sustained decreases were observed in a marker. Adverse events were similar between the groups, except for mild, generally nonrecurring injection-site reactions with romosozumab.

"Romosozumab was associated with increased and bone formation and with decreased bone resorption," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Amgen and UCB Pharma, which funded the study.

More information: Abstract
Full Text
Editorial

Related Stories

Alendronate reduces adjacent-level vertebral fractures

date Dec 30, 2013

(HealthDay)—For females with osteoporosis, the rate of adjacent-level vertebral fractures is relatively low, with reduced odds with bisphosphonate therapy, according to a study published in the Dec. 1 issue ...

Recommended for you

Combined drug treatment combats kidney disease

date 1 hour ago

A recent discovery by drug researchers whereby coupling specific cell membrane receptors has altered kidney cell function has triggered a re-think of how to treat chronic kidney disease (CKD) more effectively.

Active substance targeting dreaded hospital germs

date 1 hour ago

In the German Center for Infection Research (DZIF), scientists have conducted clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus: a highly effective protein from bacteriophages ...

S. Korea confirms 12 MERS cases (Update)

date 7 hours ago

South Korea confirmed five MERS cases Friday, bringing the total number of patients infected with the potentially deadly virus to 12, including a man who defied a quarantine protocol and travelled to China, health officials ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.